Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abnormal, accommodate, adult, advent, affinity, ahead, albumin, Alimta, alkaloid, Amnolake, amrubicin, anthracycline, antitumor, API, APL, appointed, Ariad, arimoclomal, Arizona, arsenic, assay, ATO, ATRA, Avastin, Avenue, bafetinib, Barbara, Bayer, Berlin, Biopsychology, blast, bone, borrowing, breast, bypassing, cap, cardiotoxicity, categorized, Ceflatonin, Chairmen, Chatsworth, Chemgenix, chemotherapy, chosen, chromosome, circulating, clarified, clarify, cleavage, CML, comment, complication, concomitant, condensed, consecutive, Cooperation, corroboration, CRABP, CRT, Dasatanib, dasatinib, deadline, delisted, depressed, depression, digestive, doubtful, downturn, DOXO, doxorubicin, dual, dyspnea, earnout, effusion, Eisai, Eloxatin, EMCH, emitting, environment, epithelium, Erbitux, escalating, explore, extravasation, fatal, fatigue, fever, fractional, Friedman, fusion, GAAP, gastrointestinal, Germany, Gleevec, GmbH, greatest, Hagop, heartbeat, Hedging, Hematology, hierarchy, hourly, hydrazone, Hythiam, IASB, idarubicin, Ideally, Imclone, implanted, inclusive, inflammation, ingredient, intolerance, intolerant, intravenously, irregular, Israel, Japan, Japanese, Johnson, judgment, Kantarjian, Kelly, kinase, KTB, leadership, leakage, Legend, lessen, leukemia, leukemic, likewise, linker, liver, loan, lymphocytic, Lyn, MaCRA, main, mandate, margin, markedly, marrow, MBA, meantime, medial, mouth, myelodysplastic, myeloid, myeloma, myelosuppression, Mylotarg, native, Network, nilotinib, Nippon, nonconvertible, North, Olive, OOPD, outlay, overcome, pericardial, Ph, pharmacokinetic, PhD, Philadelphia, Physiological, picoplatin, Pine, pivotal, plant, plasma, platinum, pleural, PML, Poniard, preferentially, prodrug, proliferate, prolongation, promyelocytic, proven, Psychology, PTC, pulmonary, QTc, quantification, quantity, quartile, quoted, Ramsey, randomized, randomly, RAR, RAS, receptor, recovered, recurrence, redirected, refocused, refractory, relapse, relapsed, reliance, remission, retinoic, retinoid, retreated, retroactively, rhythm, roadmap, roughly, Santa, sarcoma, SCLC, sending, shelf, Shinyaku, shutting, Simultaneously, Society, soft, solicitation, son, speaking, Sprycel, Src, succeeded, suspected, swelling, syndrome, synthetic, tamibarotene, tamiboratene, Tarceva, Tasigna, tech, temporarily, tentative, title, TMRC, topotecan, tract, translocation, Treaty, trioxide, Trisenox, TS, turn, turned, tyrosine, unacceptable, unchanged, unconsolidated, undergo, unobservable, vein, vitro, waive, Webster, won
Removed:
accelerate, activate, aggregation, amplify, Atlanta, atrophy, BLA, boosting, bulbar, cardiovascular, collaboration, constitute, consummated, controlling, CPA, damaged, decided, deposit, destruction, diseased, dismutase, ending, engineered, essential, existed, expiring, focusing, fold, halted, JJ, lethal, lifespan, mammalian, Manager, Matthew, medicinal, month, Natalizio, portfolio, recording, recruiting, refold, relocation, rental, repurchased, shape, silencing, stressful, system, tag, teleconference, worth
Filing tables
Filing exhibits
- 10-K Annual report
- 10.8 2008 Stock Incentive Plan
- 10.29 Second Amendment to Office Lease
- 10.32 Sub-sublease
- 10.33 Jack Barber Employment Agreement
- 10.34 Shi Chung NG Employment Agreement
- 10.35 Benjamin Levin Employment Agreement
- 10.36 Scott Wieland Employment Agreement
- 10.37 John Caloz Employment Agreement
- 10.38 Investment Banking Agreement
- 23.1 Consent of Bdo Seidman, LLP
- 31.1 Exhibit 31.1
- 31.2 Exhibit 31.2
- 32.1 Exhibit 32.1
- 32.2 Exhibit 32.2
Related press release
LADX similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
CytRx Corporation
Los Angeles, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S3 (Nos. 333-100947, 333-109708, 333-106629, 333-109708, 333-133269, 333-142591 and 333-147605) and Form S8 (Nos. 333-84657, 333-68200, 333-91068, 333-93305, and 333-12339) of CytRx Corporation of our reports dated March 11, 2009, relating to the consolidated financial statements and financial statement schedules, and the effectiveness of the Company’s internal control over financial reporting, which appears in this Form 10-K.
/s/ BDO Seidman, LLP
BDO Seidman, LLP
Los Angeles, California
March 11, 2009